The role of amylin in the physiology of glycemic control

Experimental and Clinical Endocrinology and Diabetes

Volumn 106, Issue 2, 1998, Pages 97-102

  Scherbaum, W A ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Amylin; Diabetes mellitus; Glycemic control; Pramlintide

Indexed keywords

AMYLIN; PEPTIDE HORMONE; PRAMLINTIDE;

CONTROLLED STUDY; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HORMONE BLOOD LEVEL; HORMONE DEFICIENCY; HORMONE RELEASE; HORMONE SUBSTITUTION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INTRAVENOUS DRUG ADMINISTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW;

EID: 0031981587     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-1211958     Document Type: Review

References (51)

1. Baron AD, Schaeffer L, Schragg P, Kolterman OG: Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetes. Diabetes 36: 274-283, 1987
2. Bennett PH: Definition, diagnosis, and classification of diabetes mellitus and impaired glucose tolerance. In: Kahn CR, Weir GC (eds.). Joslin's Diabetes mellitus, 13th edition. pp. 97-115, Lea & Febiger, Philadelphia, 1994
3. Brown K, Menius A, Sandefer E, Edwards J, James M: The effects of amylin on changes in plasma glucose and gastric emptying following an oral glucose load in conscious dogs. Diabetes 43 (Suppl 1): 172A, 1994 (Abstract)
4. Butler PC, Chou J, Carter B, Wang YN, Bu BH, Chang D, Chang JK, Rizza R: Effects of meal ingestion on plasma amylin concentrations in NIDDM and non-diabetic humans. Diabetes 39: 752-756, 1990
5. Clementi G, Caruso A, Cutuli VMC, DeBernardis E, Prato A, Amico-Roxas M: Amylin given by central or peripheral routes decreases gastric emptying and intestinal transit in the rat. Experientia 52: 677-679, 1996
6. Cockburn DC, Holt SM, Roberts AN, Cooper GJS, Reid KBM, Boyd Y: Localization of the amylin locus to chromosome 12. Cytogenet Cell Genet 51: 9677, 1989
7. Colburn WA, Gottlieb AB, Koda J, Kolterman OG: Pharmaco kinetics and pharmacodynamics of AC137 (25,28,29 tripro-amylin, human) after intravenous bolus and infusion doses in patients with insulin-dependent diabetes. J Clin Pharmacol 36: 13-24, 1996
8. Cooper GJS, Leighton B, Dimitriadis GD, Parry-Billings M, Kowalchuk JM, Howland K, Rothbard JB, Willis AC, Reid KB: Amylin found in amyloid deposits in human Type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. Proc Natl Acad Sci USA 85: 7763-7766, 1988
9. Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, Reid KB: Purification and characterization of a peptide from amyloid-rich pancreas of type 2 diabetic patients. Proc Natl Acad Sci USA 84: 8628-8632, 1987
10. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993
11. Dinneen S, Alzaid A, Turk D, Rizza R: Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia 38: 337-343, 1995
12. Ferrannini E, DeFronzo RA: Insulin actions in vivo: glucose metabolism. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P (eds.). International textbook of diabetes mellitus. pp. 409-438, John Wiley and Sons, Chichester, UK, 1992
13. Fineman MS, Giotta MP, Thompson RG, Kolterman OG, Koda JE: Amylin response following Sustacal ingestion is diminished in type II diabetic patients treated with insulin. Diabetologia 39 (Suppl. 1): A149, 1996 (Abstract)
14. Fineman MS, Koda JE, Percy A, Wareham NJ, Hales CN: Elevation of high molecular weight amylin-like peptides along with proinsulin and 32,33 split proinsulin in newly diagnosed diabetics. Diabetologia 37 (Suppl. 1): A52, 1994 (Abstract)
15. Fineman MS, Kolterman OG, Thompson RG, Koda JE: The human amylin analogue pramlintide inhibited glucagon secretion in type I diabetic subjects. Diabetes 46 (Suppl. 1): 30A, 1997 (Abstract)
16. Firth RG, Bell PM, Marsh HM, Hansen I, Rizza RA: Post-prandial hyperglycaemia in patients with noninsulin-dependent diabetes mellitus. Role of hepatic and extrahepatic tissues. J Clin Invest 77: 1525-1532, 1986
17. Frank JW, Saslow SB, Camilleri M, Thomforde GM, Dinneen S, Rizza RA: Mechanism of accelerated gastric emptying of liquids and hyperglycaemia in patients with type II diabetes mellitus. Gastroenterology 109: 755-765, 1995
18. Gedulin B, Percy A, Jodka C, Young A: Studies using neutralizing antibody and the antagonist AC187 reveal that endogenous amylin inhibits glucagon secretion. Diabetologia; 40 (suppl 1): A300, 1997a. Abstract
19. Gedulin BR, Rink TJ, Young AA: Dose-response for glucagonostatic effect of amylin in rats. Metabolism 46: 67-70, 1997b
20. Green GM, Guan D, Schwartz JG, Phillips WT: Accelerated gastric emptying of glucose in Zucker type 2 diabetic rats: role in postprandial hyperglycaemia. Diabetologia 40: 136-142, 1997
21. Hartter E, Svoboda T, Ludvik B, Schiller M, Lell B, Kuenburg E, Brunnbauer M, Woloszczuk W, Prager R: Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia 34: 52-54, 1991
22. Hwang J-H, Perseghin G, Rothman DL, Cline GW, Magnusson I, Petersen KF, Shulman GI: Impaired net hepatic glycogen synthesis in insulin-dependent diabetic subjects during mixed meal ingestion. A nuclear magnetic resonance spectroscopy study. J Clin Invest 95: 783-787, 1995
23. Janes S, Gaeta L, Beaumont K, Beeley N, Rink T: The selection of pramlintide for clinical evaluation. Diabetes 45 (Suppl. 2): A865, 1996 (Abstract)
24. Koda JE, Fineman M, Rink TJ, Dailey GE, Muchmore DB, Linarelli LG: Amylin concentrations and glucose control. Lancet 339: 1179-1180, 1992
25. Koda JE, Fineman MS, Kolterman OG, Caro JF: 24 hour plasma amylin profiles are elevated in IGT subjects vs. normal controls. Diabetes 44 (Suppl. 1): 238A, 1995 (Abstract)
26. Kolterman OG, Gottlieb A, Moyses C, Colburn W: Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC 137, a human amylin analog. Diabetes Care 18: 1179-1182, 1995
27. Kong M-F, King P, Macdonald IA, Stubbs TA, Perkins AC, Blackshaw PE, Moyses C, Tattersall RB: Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia 40: 82-88, 1997a
28. Kong M-F, Stubbs T, King P, Lambourne J, Macdonald I, Blackshaw E, Perkins A, Tattersall R: The effect of single doses of pramlintide on gastric emptying of two meals in IDDM. Diabetes 46 (Suppl. 1): 154A, 1997b (Abstract)
29. Leahy JL: Natural history of β-cell dysfunction in NIDDM. Diabetes Care 13: 992-1010, 1990
30. Lefèbvre PJ: Glucagon and its family revisited. Diabetes Care 18: 715-730, 1995
31. Leighton B, Cooper GJ: The role of amylin in the insulin resistance of non-insulin-dependent diabetes mellitus. Trends Biochem Sci 15: 295-299, 1990
32. Ludvik B, Lell B, Hartter E, Schnack C, Prager R: Decrease of stimulated amylin release precedes impairment of insulin secretion in type 2 diabetes. Diabetes 40: 1615-1619, 1991
33. Moore CX, Cooper GJS: Co-secretion of amylin and insulin from cultured islet β-cells, modulation by nutrient secretagogues, islet hormones and hypoglycemic agents. Biochem Biophys Res Commun 179: 1-9, 1991
34. Nowak TV, Johnson CP, Kalbfleisch JH, Roza AM, Wood CM, Weisbruch JP, Soergel KH: Highly variable gastric emptying in patients with insulin dependent diabetes mellitus. Gut 37: 23-29, 1995
35. Nyholm B, Ørskov L, Hove K, Gravholt CH, Møller N, Alberti KGMM, Schmitz O: The amylin analogue pramlintide decreases postprandial plasma glucose and glucagon in IDDM. Diabetes 46 (Suppl. 1): 33A, 1997 (Abstract)
36. Ørskov L, Alberti KGMM, Mengel A, Møller N, Pedersen D, Rasmussen O, Seefeldt T, Schmitz O: Decreased hepatic glucagon responses in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 34: 521-526, 1991
37. Owerbach D, Bell GI. Rutter WJ, Shows TB: The insulin gene is located on chromosome 11 in humans. Nature 286: 82-84, 1980
38. Pehling G, Tessari P, Gerich JE, Haymond MW, Service FJ, Rizza RA: Abnormal meal carbohydrate disposition in insulin-dependent diabetes. J Clin Invest 74: 985-991, 1984
39. Phillips WT, Schwartz JG, McMahan CA: Rapid gastric emptying in patients with early non-insulin-dependent diabetes mellitus. N Engl J Med 324: 130-131, 1991
40. Phillips WT, Schwartz JG, McMahan CA: Rapid gastric emptying of an oral glucose solution in type 2 diabetic patients. J Nucl Med 33: 1496-1500, 1992
41. Rink TJ, Beaumont K, Koda J, Young A: Structure and biology of amylin. Trends Pharmacol Sci 14: 113-118, 1993
42. Sanke T, Hanabusa T, Nakano Y, Oki C, Okai K, Nishimura S, Kondo M, Nanjo K: Plasma islet amyloid (amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 34: 129-132, 1991
43. Schwartz JG, McMahan CA, Green GM, Phillips WT, Guan D: Rapid gastric emptying of a solid pancake meal in type II diabetic patients. Diabetes Care 19: 468-471, 1996
44. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycaemic excursions, a measure of diabetic instability. Diabetes 1970; 19: 644-655
45. Thompson RG, Gottlieb A, Organ K, Koda J, Kisicki J, Kolterman OG: Pramlintide: a human amylin analogue reduced post-prandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes. Diabet Med 14: 547-555, 1997
46. Wallum BJ, Kahn SE, McCulloch DK, Porte D, Jr: Insulin secretion in the normal and diabetic human. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P (eds.). International textbook of diabetes mellitus. pp. 285-301, John Wiley and Sons, Chichester, UK, 1992
47. Young A, Jodka C, Green D, Gedulin B: Amylin-inhibition of gastric emptying is reversed by hypoglycemia in rats. Diabetologia 39 (Suppl. 1): A66, 1996c (Abstract)
48. Young AA, Gedulin BR, Jodka C, Green D: Insulin-induced hypoglycemia reverses amylin-inhibition of gastric emptying in rats. Diabetes 45 (Suppl. 2): 187A, 1996a (Abstract)
49. Young AA, Gedulin BR, Rink TJ: Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Metabolism 45: 1-3, 1996b
50. Young AA, Gedulin BR, Vine W, Percy A, Rink TJ: Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 38: 642-648, 1995
51. Young DA, Deems RO, Deacon RW, MacIntosh H, Foley JE: Effects of amylin on glucose metabolism and glycogenolysis in vivo and in vitro. Am J Physiol 259: E457-E461, 1990